Versant Capital Management Inc Increases Stake in 10x Genomics, Inc. (NASDAQ:TXG)

Versant Capital Management Inc grew its position in shares of 10x Genomics, Inc. (NASDAQ:TXG) by 4,184.4% in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 12,082 shares of the company’s stock after buying an additional 11,800 shares during the quarter. Versant Capital Management Inc’s holdings in 10x Genomics were worth $105,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of the company. RA Capital Management L.P. purchased a new position in shares of 10x Genomics in the 4th quarter valued at about $47,092,000. D. E. Shaw & Co. Inc. acquired a new stake in shares of 10x Genomics in the fourth quarter valued at about $17,499,000. ARK Investment Management LLC lifted its stake in shares of 10x Genomics by 11.1% in the fourth quarter. ARK Investment Management LLC now owns 11,944,057 shares of the company’s stock valued at $171,517,000 after purchasing an additional 1,193,712 shares during the period. Two Sigma Investments LP lifted its stake in shares of 10x Genomics by 291.2% in the fourth quarter. Two Sigma Investments LP now owns 1,319,487 shares of the company’s stock valued at $18,948,000 after purchasing an additional 982,203 shares during the period. Finally, Two Sigma Advisers LP lifted its stake in shares of 10x Genomics by 240.6% in the fourth quarter. Two Sigma Advisers LP now owns 1,236,200 shares of the company’s stock valued at $17,752,000 after purchasing an additional 873,200 shares during the period. Hedge funds and other institutional investors own 84.68% of the company’s stock.

Analyst Ratings Changes

Several analysts recently commented on TXG shares. Stifel Nicolaus reduced their price objective on shares of 10x Genomics from $21.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday, February 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of 10x Genomics in a research note on Saturday, May 24th. Morgan Stanley reduced their price objective on shares of 10x Genomics from $26.00 to $18.00 and set an “overweight” rating for the company in a research note on Monday, May 19th. Stephens restated an “overweight” rating and set a $14.00 target price on shares of 10x Genomics in a report on Thursday, May 15th. Finally, The Goldman Sachs Group dropped their target price on shares of 10x Genomics from $7.50 to $6.50 and set a “sell” rating for the company in a report on Monday, May 12th. One analyst has rated the stock with a sell rating, eight have given a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $15.81.

10x Genomics Price Performance

NASDAQ:TXG opened at $9.11 on Wednesday. The firm has a 50 day simple moving average of $8.45 and a 200-day simple moving average of $11.76. The firm has a market cap of $1.12 billion, a PE ratio of -5.99 and a beta of 1.94. 10x Genomics, Inc. has a 1-year low of $6.78 and a 1-year high of $24.76.

10x Genomics (NASDAQ:TXG) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.09. 10x Genomics had a negative net margin of 29.90% and a negative return on equity of 25.40%. The business had revenue of $154.88 million during the quarter, compared to analyst estimates of $131.91 million. During the same quarter in the previous year, the business posted ($0.50) earnings per share. The company’s revenue was down 2.3% on a year-over-year basis. As a group, sell-side analysts expect that 10x Genomics, Inc. will post -1.43 earnings per share for the current fiscal year.

Insider Activity at 10x Genomics

In related news, CFO Adam Taich sold 4,044 shares of the business’s stock in a transaction that occurred on Thursday, May 22nd. The shares were sold at an average price of $8.30, for a total value of $33,565.20. Following the completion of the sale, the chief financial officer now directly owns 331,588 shares in the company, valued at approximately $2,752,180.40. The trade was a 1.20% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Benjamin J. Hindson sold 7,485 shares of 10x Genomics stock in a transaction that occurred on Thursday, May 22nd. The shares were sold at an average price of $8.30, for a total transaction of $62,125.50. Following the transaction, the insider now directly owns 448,374 shares in the company, valued at approximately $3,721,504.20. This trade represents a 1.64% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 20,872 shares of company stock worth $173,238. 9.39% of the stock is owned by company insiders.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.